Dataset Information


Targeted therapeutic options and future perspectives for HER2-positive breast cancer.

ABSTRACT: Over the past 2 decades, there has been an extraordinary progress in the regimens developed for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Trastuzumab, pertuzumab, lapatinib, and ado-trastuzumab emtansine (T-DM1) are commonly recommended anti-HER2 target agents by the U.S. Food and Drug Administration. This review summarizes the most significant and updated research on clinical scenarios related to HER2-positive breast cancer management in order to revise the guidelines of everyday clinical practices. In this article, we present the data on anti-HER2 clinical research of neoadjuvant, adjuvant, and metastatic studies from the past 2 decades. We also highlight some of the promising strategies that should be critically considered. Lastly, this review lists some of the ongoing clinical trials, findings of which may soon be available.


PROVIDER: S-EPMC6799843 | BioStudies | 2019-01-01

REPOSITORIES: biostudies

Similar Datasets

2014-01-01 | S-EPMC4260046 | BioStudies
2015-01-01 | S-EPMC4622301 | BioStudies
2019-01-01 | S-EPMC6720931 | BioStudies
2016-01-01 | S-EPMC6075965 | BioStudies
2020-01-01 | S-EPMC7293079 | BioStudies
2017-01-01 | S-EPMC5455677 | BioStudies
1000-01-01 | S-EPMC5084478 | BioStudies
2019-01-01 | S-EPMC6784849 | BioStudies
2015-01-01 | S-EPMC4439018 | BioStudies
2014-01-01 | S-EPMC4180403 | BioStudies